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ABSTRACT 
Pleurotus sajor-caju (PSC) was believed to have both antihyperlipidemic and hepatoprotective 
activities. The present study aimed to investigate the effect of PSC on liver enzymes and histological 
integrity. This study used five groups of rats fed with ghee in the ratio 32g ghee per 68g pellet to 
induce hypercholesterolemia and one group was fed on cholesterol free basal diet. Rats treated with 
100 mg/kg of PSC for a month was found to have an effect on the liver enzymes activities since 
plasma alkaline phosphatase (ALP) concentration in this group showed a significant reduction 
(P<0.05) and a higher percentage reduction (66.01%) as compared to 20 mg/kg-PSC and 200 mg/kg-
PSC treatment groups.  The plasma aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) only showed a mild increased by 35.04% and 15.00% respectively in 100 mg/kg-PSC treatment 
group and there was no significant increased (P>0.05) found in these both AST and ALT 
concentrations. Atorvastatin treatment also showed reduction in ALP enzymes but no significant 
reduction (P>0.05) as compared to 100 mg/kg-PSC treatment group. On the other hand, plasma AST 
and ALT in 20 mg/kg of atorvastatin treatment were increased in percentage by 275.97% and 112.50% 
respectively indicated the adverse effects of statin in term of elevation of plasma enzymes activities. 
On the histological part, there was no significant finding in the micrograph study between treatment 
and hypercholesterolemic (HPC) liver rat. The micrograph of rat liver treated with 100 mg/kg PSC 
showed smooth and clear surface of hepatocytes compared to HPC group. 
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INTRODUCTION 
Edible mushrooms have been world widely cultivated mainly for food, health and medicinal 
purposes. These fungi are commonly cultivated on decayed organic material while producing 
edible portion on the surface of the substrate. Pleurotus sajor-caju (PSC), also known as oyster 
mushrooms, is easily cultivated and is done so widely in the tropical regions and many other 
parts of the world. It is reported to possess distinctive aroma and highly palatable.  
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In South East Asian countries, oyster mushroom is widely used in the preparation of vegetable, 
soup, stew and other culinary products. This edible fungus is suggested to possess considerable 
importance in the human diet as its rich in non-starchy carbohydrates, dietary fibre, β-glucans, 
minerals, vitamin B while having low in fat. β-glucans, also a components of soluble or insoluble 
dietary fibre (SDF, IDF) is present in appreciable amounts in mushrooms and are linked to the 
ability to lower blood cholesterol levels and glycaemic response in vivo (Manzi et al., 2004), 
hypercholesterolemic properties and other therapeutic functions. The present study was 
conducted to investigate whether Pleurotus sajor-caju extract affect liver enzymes and 
histological integrity.  
 
METHODS AND MATERIALS 
Pleurotus sajor-caju 
Oyster mushroom (Pleurotus sajor-caju, PSC) was supplied by Anjaad Industries Sdn Bhd 
(Serkam, Malacca State of Malaysia). PSC mushroom was already in the ground dried form. 
Aqueous extract of PSC was extracted using Soxhlet apparatus.  
Animals 
The procedure and protocol described below were approved by Animal Ethics Committee USM 
(USM/Animal Ethics Approval/ 2013/ (83) (446)). Eighteen male Wistar rats weighing 250-370 
g were obtained from Animal Research and Service Centre of Universiti Sains Malaysia 
(ARASC). For adaptation, the rats were fed with a basal diet for one week before treatment 
begins. They were housed in rat cages at room temperature of 22 ± 1°C under a 12-h light-dark 
cycle. Rats were divided randomly into six feed groups (3 rats/group): control group was fed a 
basal diet; while the remaining five groups were given 32 g ghee per 68 g pellet (high-cholesterol 
diet). Rats were fed for two weeks and were allowed free access to water. After two weeks of 
high-cholesterol diet, blood was withdrawn from the rats through saphenous vein. Blood samples 
were then sent to BP Laboratory Pte Ltd for total cholesterol levels determination. Plasma total 
cholesterol was determined using automated Abbott Ci8200 Biochemistry analyzer based on 
enzymatic kits methods. Rat with serum cholesterol level > 2.3 mmol/L was considered 
hypercholesterolemic and included in this study. Group I was served as normal control (NC) rats, 
whereas Group II was left as a hypecholesterolemic (HPC) control rats. Meanwhile Group III, 
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IV, V and VI were treated with 20 mg/kg PSC, 100 mg/kg PSC, 200 mg/kg PSC and 20 mg/kg 
atorvastatin respectively.  
Plasma enzymes analysis 
At the end of experiment, the rats were anaesthetized with 6% pentobarbital and blood was 
collected through cardiac puncture and sent to the BP Laboratory for liver function tests (LFTs) 
analysis. Plasma liver enzymes were determined using automated Abbott Ci8200 Biochemistry 
analyzer based on photometric IFCC (Intrenational Federation of Chemistry) methods. 
Histological analysis of liver by using scanning electron microscope (SEM) 
Liver tissues were rapidly dissected, removed and fixed in McDowel-Trump Fixative at 4°C for 
24 hours. The fixed tissues were then cut, washed, post-fixed and dehydrated. The sample was 
then proceed with critical point drying step, coated with gold and lastly viewed under Quanta 
FEG 450 Scanning Electron Microscope (SEM) by using XTm Product Version 4.1.7.2095 
viewer software. 
Statistical analysis 
All values used in analysis are presented as means ± SEM. Comparisons among the different 
groups were performed by one-way analysis of variance (ANOVA), followed by Bonferroni 
multiple comparisons test and differences were considered significant when P < 0.05. 
 
RESULTS AND DISCUSSION 
Effects of PSC on plasma liver enzyme profile 
Table 1 summarizes the values for all liver enzyme analysis before and after treatments. There 
were no significant differences found in total protein, albumin, globulin, and albumin/globulin 
(A/G) ratio for all experimental groups. AST level in 20mg/kg-PSC, 200mg/kg-PSC and HPC 
group was increased in percentage changes by 127.50%, 85.39% and 147.22% respectively. Like 
AST, there was an increased in ALT by 65.79%, 23.40% and 53.49% respectively for 20mg/kg-
PSC, 200 mg/kg-PSC treatment and HPC group of rats. The least amount of increase in AST and 
ALT were found in 100 mg/kg-PSC treatment group (35.04% and 15.00% respectively). In 
contrast, the highest increased in AST and ALT were found in atorvastatin treatment group 
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(275.97% and 112.5% respectively). ALP level in 20mg/kg-PSC, 200mg/kg-PSC and 20mg/kg-
atorvastatin treatment group was increased in percentage changes by 49.40%, 52.95% and 
54.97% respectively. A significant reduction by 66.47% and 66.01% was found in HPC and 
100mg/kg-PSC treatment groups respectively. There were no changes observed before and after 
treatment in both total bilirubin and GGT enzymes. 
 
Lower plasma ALP concentration in hypercholesterolemic rats was assessed to significantly (P < 
0.05) reduced by the supplementation of diet with 100 mg/kg PSC (Figure 1). Treatment with 20 
mg/kg and 200 mg/kg of PSC were not significantly (P > 0.05) differed in their impact on ALP 
enzyme. Thus, by comparing to other treatment groups, dose of 100 mg/kg of PSC was the 
effective dose of PSC to lower the plasma ALP. However, this finding was not significant as 
HPC group was also found to have significantly reduction in plasma ALP (P > 0.05). The reason 
for such result may be due to the modulation of mechanism or physiological functions in 
hypercholesterolemic rats which cannot be controlled. ALP is a marker enzyme of the plasma 
membrane and can be found mainly in liver and bone origin. The underlying mechanism for 
reduction of plasma ALP enzymes by mushroom is not clearly understood. However, study by 
Mishra and Singh (2010), had comes out with a finding that mushroom (Pleurotus sp.) restores 
the changes in ALP, AST and ALT activities due to antioxidant effects and their ability as a 
radical scavenger, thus, protecting membrane permeability. 
 
Plasma AST and ALT was found to be elevated in all groups. However, there was no significant 
increased (P > 0.05) found for both enzymes (Figure 2 and 3). Increased in plasma AST and 
ALT was more prominent in 20mg/kg PSC-treatment, atorvastatin treatment and 
hypercholesterolemic control groups. From the result, we found that 20mg/kg of PSC-treatment 
was the least effective treatment compared to the other two PSC-treatment groups. On the other 
hand, plasma AST and ALT concentrations for 100mg/kg PSC treatment was increased by 
35.04% and 15.00% respectively which is the smallest percentage of increased in concentration 
as compared to HPC and other PSC-treatment groups. 
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In this study, atorvastatin treatment served as positive control group, thus, the results should be 
almost similar with PSC treatment group. However, by comparing with HPC and PSC treatment 
groups, we found another finding in which AST and ALT levels in 20 mg/kg atorvastatin 
treatment group showed a significant increased by 275.97% and 112.50% respectively. Thus, we 
can postulate that increased in these two liver enzyme parameters may be due to statin adverse 
effects. There is a correlation exists between statin treatment and hepatic adverse effects. 
However, the underlying mechanism of this effect is still not clearly understood. Previous study 
had postulated that statin causes changes in the lipid components of the hepatocyte membrane 
and this will leads to an increase in its permeability and result in an increased of liver enzymes 
(Rossana et al., 2010). 
 
Figure 3 - 7 showed no significant different (P > 0.05) in plasma total protein, albumin, globulin 
and A/G ratio respectively for all treatments. There were also no changes in concentration of pre- 
and post-study for total bilirubin and GGT concentration (Table 1). In addition, there were also 
no significant differences of total protein within groups (P > 0.05) in both pre and post-treatment 
of PSC and atorvastatin on total protein level of HPC rats (Figure 4). On the other part, the effect 
of pre and post-treatment of PSC and atorvastatin on plasma albumin of HPC rats resulted 
reduction in albumin values for all groups, however there were no significant decreased of 
albumin (Figure 5) within groups (P>0.05). In addition, globulin level was decreased for 20 
mg/kg and 100 mg/kg-PSC treatment groups, but increased for other groups. However, there 
were no significant differences of globulin levels (Figure 6) within groups (P > 0.05). In 
addition, albumin/globulin ratio (A/G) of HPC rats’ ratio was reduced in normal, HPC, 200 
mg/kg-PSC and 20 mg/kg atorvastatin treatment groups, whereas other groups showed no 
changes in values (Figure 7). There were no significant differences of A/G ratio within groups (P 
> 0.05). 
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Table 1 Effect of Pleurotus sajor-caju on liver enzymes of hypercholesterolemic rats 
Group Treatment TP (g/L) 
Alb 
(g/L) 
Glo 
(g/L) A/G 
TB 
(μmol/L) 
SGOT/AST 
(U/L) 
SGPT/ALT 
(U/L) 
ALP 
(U/L) 
GGT 
(U/L) 
I 
(Normal 
control, NC) 
Before  61.5±1.5 24.0±2.0 37.5±0.5 0.70±0.05 1.7 129.0±7.0 40.0±1.5 362.0 ± 58.0 4 
After 61.5±2.5 23.0±0.5 39.0±2.0 0.60±0.0 1.7 215.0±80.0 61.0±15.5 254.0±23.0 4 
% changes - -4.17 +4.00 -14.29 - +66.67 +52.50 -29.83 - 
II 
(HPC) 
Before  60.0±1.5 24±1.0 35.5±0.5 0.70±0.05 1.7 126.0±17.0 43.0± 2.0 854.5±23.5 4 
After 57.5±0.7 22±0.5 36.0±1.0 0.6±0.0 1.7 311.5±169.5 66±18.5 286.5±12.5 4 
% changes -4.17 -8.33 +1.41 -14.29 - +147.22 +53.49 -66.47* - 
III 
(20 mg/kg-
PSC) 
Before  62.0±2.0 25±0.9 36.7±1.5 0.7± 0.03 1.7 120.0±7.4 38±1.8 585.0±62.6 4 
After 58.3±2.3 23.0±1.2 35.3±1.5 0.7±0.03 1.7 273.0±65.2 63.0±10.2 296.0±39.5 4 
% changes -5.97 -8.00 -3.81 - - +127.50 +65.79 -49.40 - 
IV 
(100 mg/kg-
PSC) 
Before  62.0±0.3 25± 0.9 37.0±1.0 0.70±0.06 1.7 122.7±11.2 40.0±2.3 823.7±133.4 4 
After 58.3±1.2 24.0±0.0 34.3±1.2 0.7±0.03 1.7 165.7±38.1 46.0±4.4 280.0±14.1 4 
% changes -5.97 -4.00 -7.30 - - +35.04 +15.00 -66.01* - 
V 
(200 mg/kg-
PSC) 
Before  58.0±3.2 24.0±1.0 34.0±2.3 0.8±0.1 1.7 130.7±22.8 47.0±7.0 672.3±65.9 4 
After 61.0±1.2 24.0±0.6 37.0±1.0 0.6± 0.03 1.7 242.3±84.4 58.0±13.3 316.3±37.9 4 
% changes +5.17 - +8.82 -25.00 - +85.39 +23.40 -52.95 - 
VI 
(20 mg/kg- 
Atorvastatin) 
Before  63.7±0.9 25.0±0.6 38.7±0.7 0.5±0.1 1.7 115.7±6.2 40.0 ±1.8 791.3±124.7 4 
After 60.7±0.7 22.0±0.9 39.0±0.6 0.6± 0.03 1.7 435.0±243.4 85.0±30.8 356.3±43.2 4 
% changes -4.71 -12.00 +0.78 +20.00 - +275.97 +112.50 -54.97 - 
Values are expressed as means ± SEM for each group; * indicates significantly different at P < 0.05. TP: 
total protein (g/L); Alb: albumin (g/L); Glo: Globulin (g/L); A/G: albumin/globulin ratio; TB: total 
bilirubin (μmol/L); SGOT/AST: serum glutamic oxaloacetic transaminase/aspartate transaminase (U/L); 
SGPT/ALT: serum glutamic pyruvate transaminase/alanine aminotransferase (U/L); ALP: alkaline 
phosphatase (U/L); GGT: gamma-glutamyl transpeptidase (U/L). 
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Graph of ALP values pre- vs. post-treatment groups
NC
-pr
e
NC
-po
st
HP
C-
pr
e
HP
C-
po
st
20
mg
/kg
-pr
e
20
mg
/kg
-po
st
10
0m
g/k
g-p
re
10
0m
g/k
g-p
os
t
20
0m
g/k
g-p
re
20
0m
g/k
g-p
os
t
20
mg
/kg
 at
or
va
-pr
e
20
mg
/kg
 at
or
va
-po
st
0
500
1000
1500
* *
Groups
A
LP
 (U
/L
)
 
Graph of AST values pre- vs. post-treatment groups
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Fig 1 Effect of pre- and post-treatment of PSC and 
atorvastatin on plasma alkaline phosphatase (ALP) of 
HPC rats. Values are in means ± SEM. 
*indicates significantly different at P < 0.05.  
NC = normal control, HPC = hypercholesterolemic 
Fig 2 Effect of pre and post-treatment of PSC and 
atorvastatin on plasma aspartate aminotransferase 
(AST) of HPC rats. Values are in means ± SEM.  
NC = normal control, HPC = hypercholesterolemic  
Graph of ALT values pre- vs. post-treatment groups
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Graph of total protein pre- vs. post-treatment groups
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Fig 3 Effect of pre and post-treatment of PSC and 
atorvastatin on plasma alanine aminotransferase 
(ALT) of HPC rats. Values are in means ± SEM.  
NC = normal control, HPC = hypercholesterolemic  
Fig 4 Effect of pre and post-treatment of PSC and 
atorvastatin on total protein level of HPC rats. Values 
are in means ± SEM.  
NC = normal control, HPC = hypercholesterolemic  
ANNALS OF MICROSCOPY                                                                                            Vol 14, April 2014 
 
8 
 
Graph of albumin pre- vs. post-treatment groups
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Graph of globulin pre- vs. post-treatment groups
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Fig 5 Effect of pre and post-treatment of PSC and 
atorvastatin on plasma albumin of HPC rats. Values 
are in means ± SEM.  
NC = normal control, HPC = hypercholesterolemic  
Fig 6 Effect of pre and post-treatment of PSC and 
atorvastatin on globulin level of HPC rats. Values are 
in means ± SEM.  
NC = normal control, HPC = hypercholesterolemic  
 
Graph of A/G ratio pre- vs. post-treatment groups
NC
-p
re
NC
-p
os
t
HP
C-
pr
e
HP
C-
po
st
20
mg
/kg
-p
re
20
mg
/kg
 po
st
10
0m
g/k
g-
pr
e
10
0m
g/k
g-
po
st
20
0m
g/k
g-
pr
e
20
0m
g/k
g-
po
st
20
mg
/kg
 at
or
va
-p
re
20
mg
/kg
 at
or
va
-p
os
t
0.0
0.2
0.4
0.6
0.8
1.0
Groups
A
/G
 ra
tio
 
Fig 7 Effect of pre and post-treatment of PSC and 
atorvastatin on albumin/globulin ratio (A/G) of HPC 
rats. Values are in means ± SEM.  
NC = normal control, HPC = hypercholesterolemic  
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Histological study 
Scanning electron microscope (SEM) indicated three-dimensional features of intrahepatic 
structures in liver rat especially the surface characteristics of hepatocytes and sinusoidal 
endothelial cells. At 4000 x magnification, HPC rat liver treated with 100 mg/kg-PSC (Figure 
8a) showed smooth surface of hepatocytes with bile canaliculi as compared to HPC rat (Figure 
8c). Hepatocytes seen were in polyhedral and sharply angulated shape. However, the surface 
seen was not so clear due to the presence of some artifact. Figure 8b showed micrograph of HPC 
rat liver treated with atorvastatin in which the morphological features of liver surface resembled 
PSC-treatment (Figure 8a) to some extent. However, the surface of hepatocytes seen in 
atorvastatin treatment was not as smooth as PSC-treatment. This may be due to the incorrectly 
apply technique in the process of cutting the liver.  
 
In addition, at 12 000 X magnification, rat liver after 100 mg/kg PSC treatment and atorvastatin 
treatment demonstrated smooth surface of hepatocytes as compared to HPC control rat (Figure 
9a-9d). Round structure with whitish color may be assumed as fat storing cells or fatty 
infiltration but were not clearly seen. Normal control rat showed these whitish round structures 
but not as prominent as HPC rat. At higher magnification (30 000 X), round structure with 
whitish color may be assumed as fat storing cells or fatty infiltration but are not clearly seen 
(Figure 10a-10d). Normal control rat (Figure 10d) showed these whitish round structures 
measuring about 0.8 μm but not as prominent as HPC (Figure 10c) rat. A small amount of fats 
storing cells or fatty infiltration may present in 100 mg/kg and atorvastatin treatment rat liver but 
are not clearly seen and not prominent in HPC rat. 
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Fig 8 (a): Micrograph of rat liver after 100 mg/kg PSC treatment; (b): atorvastatin treatment; (c): HPC 
control; (d): normal control. (H: hepatocytes; arrowhead: bile canaliculi; BV: blood vessel) (4 000 x 
magnification) 
 
 
 
 
 
 
(a) 100mg/kg PSC (b) 20mg/kg atorvastatin 
(c) HPC rat  (d) NC 
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Fig 9 (a): Micrograph of rat liver after 100 mg/kg PSC treatment; (b): atorvastatin treatment; (c): HPC 
control; (d): normal control. (H: hepatocytes; arrowhead: bile canaliculi; BV: blood vessel; R: red blood 
cell) (12 000 x magnification) 
 
 
 
 
 
 
 
(a) 100mg/kg PSC (b) 20mg/kg atorvastatin 
(c) HPC rat  (d) NC 
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Fig 10 (a): Micrograph of rat liver after 100 mg/kg PSC treatment; (b): atorvastatin treatment; (c): HPC 
control; (d): normal control. (H: hepatocytes; arrowhead: bile canaliculi; BV: blood vessel; R: red blood 
cell) (30 000 x magnification) 
 
CONCLUSION 
 
This preliminary study demonstrated that feeding 100 mg/kg of PSC significantly reduced 
plasma ALP concentration. However, this finding was not significant as HPC group also showed 
significant reduction in ALP enzymes. Atorvastatin drug was proven to have clinically 
significant adverse effects as an elevated ALT and AST enzymes were prominent in 20 mg/kg 
atorvastatin-treatment group as compared to PSC-treatment groups. However, there was no 
(a) 100mg/kg PSC (b) 20mg/kg atorvastatin 
(c) HPC rat  (d) NC 
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significant finding on the micrograph study on the liver of HPC and PSC-treatment rat. The only 
different in this histological study is the surface of hepatocyte in PSC- and atorvastatin treatment 
rat was smooth as compared to HPC rat. For future work, it is suggested to used normal light 
microscopic staining (Haematoxylin and Eosin, H&E and Oil-Red staining) or TEM to study for 
any fatty infiltration and fatty changes in HPC and treatment rats. 
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